Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Bopp, A ^a,b   Wartlick, F ^a,b   Henninger, C ^a   Kaina, B ^b   Fritz, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Aging; Fibrosis; Genotoxic stress response; Hepatotoxicity; Rac1; Small GTPases

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DOXORUBICIN; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 1B; HISTONE H2AX; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROTEIN P16; RAC1 PROTEIN; RAD51 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WERNER SYNDROME PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; ACTIN; ALPHA SMOOTH MUSCLE ACTIN, MOUSE; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; CTGF PROTEIN, MOUSE; H2AFX PROTEIN, HUMAN; HISTONE; MUTAGENIC AGENT; NEUROPEPTIDE; RAC PROTEIN; RAC1 PROTEIN, MOUSE;

ACUTE TOXICITY; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENOTOXICITY; HISTONE PHOSPHORYLATION; IONIZING RADIATION; LIVER DEVELOPMENT; LIVER FIBROSIS; LIVER TOXICITY; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; STRESS; TISSUE CHARACTERIZATION; ANIMAL; APOPTOSIS; DRUG EFFECT; FEMALE; FIBROSIS; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; LIVER; MALE; METABOLISM; MOUSE MUTANT; OXIDATIVE STRESS; PATHOLOGY; RADIATION EXPOSURE; SIGNAL TRANSDUCTION;

ANIMALIA; MUS;

ACTINS; AGING; ANIMALS; APOPTOSIS; CONNECTIVE TISSUE GROWTH FACTOR; DNA DAMAGE; DOXORUBICIN; FEMALE; FIBROSIS; GAMMA RAYS; GENE EXPRESSION REGULATION; HISTONES; LIVER; MALE; MICE; MICE, KNOCKOUT; MUTAGENS; NEUROPEPTIDES; OXIDATIVE STRESS; RAC GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84875906348     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.57     Document Type: Article

References (54)

1. Bokoch GM. Regulation of cell function by Rho family GTPases. Immunol Res 2000; 21: 139-148.
2. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
3. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995; 81: 1147-1157.
4. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137-1146.
5. Hordijk PL. Regulation of NADPH oxidases: The role of Rac proteins. Circ Res 2006; 98: 453-462.
6. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11: 463-475.
7. Canman CE, Kastan MB. Three paths to stress relief. Nature 1996; 384: 213-214.
8. Mazars A, Tournigand C, Mollat P, Prunier C, Ferrand N, Bourgeade MF et al. Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta. Oncogene 2000; 19: 1277-1287.
9. Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: Control by Rac1. Mol Cancer 2011; 10: 67.
10. Hu Y, Hu X, Boumsell L, Ivashkiv LB. IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways. J Immunol 2008; 180: 8057-8065.
11. Maroto B, Ye MB, von Lohneysen K, Schnelzer A, Knaus UG. P21-activated kinase is required for mitotic progression and regulates Plk1. Oncogene 2008; 27: 4900-4908.
12. Halet G, Carroll J. Rac activity is polarized and regulates meiotic spindle stability and anchoring in mammalian oocytes. Dev Cell 2007; 12: 309-317.
13. Sandrock K, Bielek H, Schradi K, Schmidt G, Klugbauer N. The nuclear import of the small GTPase Rac1 is mediated by the direct interaction with karyopherin alpha2. Traffic 2010; 11: 198-209.
14. Schmitz AA, Govek EE, Bottner B, Van Aelst L. Rho GTPases: Signaling, migration, and invasion. Exp Cell Res 2000; 261: 1-12.
15. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 2007; 67: 8089-8094.
16. Mulloy JC, Wunderlich M, Zheng Y, Wei J. Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling. Cell Cycle 2008; 7: 3314-3319.
17. Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood 2011; 118: 5235-5245.
18. Walmsley MJ, Ooi SK, Reynolds LF, Smith SH, Ruf S, Mathiot A et al. Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 2003; 302: 459-462.
19. Wells CM, Walmsley M, Ooi S, Tybulewicz V, Ridley AJ. Rac1-deficient macrophages exhibit defects in cell spreading and membrane ruffling but not migration. J Cell Sci 2004; 117(Pt 7): 1259-1268.
20. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: Potential candidates for anticancer therapy. Cancer Lett 2004; 206: 181-191.
21. Ellenbroek SI. Collard JG. Rho GTPases: Functions and association with cancer. Clin Exp Metastasis 2007; 24: 657-672.
22. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
23. Zhou Q, Liao JK. Pleiotropic effects of statins - basic research and clinical perspectives. Circ J 2010; 74: 818-826.
24. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline- induced cardiac toxicity. Cell Death Dis 2011; 2: E190.
25. Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathe D et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007; 13(18 Pt 1): 5331-5340.
26. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-370.
27. Hamalukic M, Huelsenbeck J, Schad A, Wirtz S, Kaina B, Fritz G. Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors. Plos One 2011; 6: E26413.
28. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5: 221-225.
29. Haydont V, Bourgier C, Vozenin-Brotons MC. Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol 2007; 80: 32-40.
30. Sugihara K, Nakatsuji N, Nakamura K, Nakao K, Hashimoto R, Otani H et al. Rac1 is required for the formation of three germ layers during gastrulation. Oncogene 1998; 17: 3427-3433.
31. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
32. Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 2009; 8: 1075-1085.
33. Damrot J, Nuebel T, Epe B, Roos WP, Kaina B, Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 2006; 149: 988-997.
34. Huelsenbeck SC, Schorr A, Roos WP, Huelsenbeck J, Henninger C, Kaina B et al. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem 2012; 287: 38590-38599.
35. Henninger C, Huelsenbeck J, Huelsenbeck S, Grosch S, Schad A, Lackner KJ et al. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol 2012; 261: 66-73.
36. Olive PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 2004; 75: 355-373.
37. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008; 36: 5678-5694.
38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
39. Nuebel T, Damrot J, Roos WP, Kaina B, Fritz G. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res 2006; 12: 933-939.
40. Ostrau C, Hulsenbeck J, Herzog M, Schad A, Torzewski M, Lackner KJ et al. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother Oncol 2009; 92: 492-499.
41. Fritz G, Henninger C, Huelsenbeck J. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. Br Med Bull 2011; 97: 17-26.
42. Bourgier C, Haydont V, Milliat F, Francois A, Holler V, Lasser P et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005; 54: 336-343.
43. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009; 47: 698-705.
44. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69: 695-699.
45. Haydont V, Gilliot O, Rivera S, Bourgier C, Francois A, Aigueperse J et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol Biol Phys 2007; 68: 1471-1482.
46. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 1989; 264: 16378-16382.
47. van Helden SF, Anthony EC, Dee R, Hordijk PL. Rho GTPase expression in human myeloid cells. PLoS One 2012; 7: E42563.
48. Guo F, Cancelas JA, Hildeman D, Williams DA, Zheng Y. Rac GTPase isoforms Rac1 and Rac2 play a redundant and crucial role in T-cell development. Blood 2008; 112: 1767-1775.
49. Glogauer M, Marchal CC, Zhu F, Worku A, Clausen BE, Foerster I et al. Rac1 deletion in mouse neutrophils has selective effects on neutrophil functions. J Immunol 2003; 170: 5652-5657.
50. Cox D, Chang P, Zhang Q, Reddy PG, Bokoch GM, Greenberg S. Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J Exp Med 1997; 186: 1487-1494.
51. Duran RV, Hall MN. Regulation of TOR by small GTPases. EMBO Rep 2012; 13: 121-128.
52. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM et al. Rapamycininduced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-1643.
53. Wang Z, Thurmond DC. Differential phosphorylation of RhoGDI mediates the distinct cycling of Cdc42 and Rac1 to regulate second-phase insulin secretion. J Biol Chem 2010; 285: 6186-6197.
54. Ueda S, Kitazawa S, Ishida K, Nishikawa Y, Matsui M, Matsumoto H et al. Crucial role of the small GTPase Rac1 in insulin-stimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma. FASEB J 2010; 24: 2254-2261.